Are You Eligible for New Kidney Medications? Questions to Ask Your Doctor

The New Arsenal: What Has Changed Since Yesterday’s Treatment

For decades, doctors had exactly two classes of kidney-protective medications: ACE inhibitors and angiotensin II receptor blockers (ARBs). Both lowered blood pressure and offered some protection against kidney damage, but their ceiling was fixed. Then came the breakthrough: three new medication classes arrived with clinical evidence that fundamentally altered what is possible.

SGLT2 inhibitors (often called “Flozins”) work by a counterintuitive mechanism – they prevent your kidneys from reabsorbing sugar, allowing excess glucose to leave through urine instead. The clinical evidence is striking: randomised trials show they reduce the risk of kidney failure by 30 to 40 percent. Four FDA-approved options exist in this class:

Farxiga (Dapagliflozin) – prevents sugar reabsorption
Jardiance (Empagliflozin) – removes excess sugar and salt
Invokana (Canagliflozin) – lowers blood sugar and reduces strain on kidneys and heart
Steglatro (Ertugliflozin) – removes excess sugar through urine
The critical eligibility threshold: SGLT2 inhibitors are approved for people with kidney disease at eGFR levels as low as 20 – meaning even those in CKD stage 4 (advanced kidney disease) can access them.

Finerenone (brand name Kerendia) represents an entirely different mechanism. It blocks aldosterone, a hormone that contributes to kidney scarring and fibrosis. By preventing that scarring process, finerenone may preserve kidney function longer. The FDA approval came with specific parameters: you need type 2 diabetes-associated kidney disease, an eGFR above 25, and a urine-albumin creatinine ratio above 30.

GLP-1 receptor agonists were originally designed for blood sugar control, but their kidney benefits have proven substantial. They slow disease progression, reduce inflammation, lower blood pressure, decrease protein in urine, and improve heart health. The clinical evidence includes a 24 percent lower risk of major kidney events reported in large trials for semaglutide (Ozempic/Wegovy). Available medications in this class include:

Semaglutide (Ozempic or Wegovy)
Tirzepatide (Mounjaro or Zepbound)
Liraglutide (Victoza or Saxenda)
These three classes represent genuine innovation. But eligibility is not universal, and the wrong medication for your specific condition wastes money and opportunity.

The First Question: Do You Actually Know Your Kidney Numbers?

Before any conversation about medication eligibility happens, you need baseline data. Your doctor should have ordered two tests: eGFR (estimated glomerular filtration rate) and urine-albumin creatinine ratio (UACR). The eGFR tells you what percentage of kidney function remains; the UACR measures protein leakage into urine, a sign of kidney stress.

Here is what disqualifies many people from new medications: they never asked for these numbers, or they received results without context. You cannot assess eligibility without them. Request a copy of your most recent labs and ask your doctor to explain what the numbers mean in plain language.

eGFR above 90: Normal kidney function
eGFR 60–89: Mild kidney disease
eGFR 30–59: Moderate kidney disease
eGFR 15–29: Severe kidney disease
eGFR below 15: Kidney failure (may require dialysis)
Different medications have different thresholds. SGLT2 inhibitors work down to eGFR 20. Finerenone requires eGFR above 25. GLP-1 agonists have broader eligibility but are primarily indicated for those with type 2 diabetes. Know your number before the appointment.

The Second Question: What Caused Your Kidney Disease?

Knowing the cause of your chronic kidney disease ensures you receive the right treatment. This is not academic – it determines which medication class makes sense.

If you have type 2 diabetes with kidney disease, all three new classes are potentially relevant. Ask your doctor about SGLT2 inhibitors first, then finerenone, then GLP-1 agonists. The combination effect can be powerful.
If you have IgA nephropathy or another non-diabetic kidney disease, SGLT2 inhibitors still apply, but finerenone and GLP-1 agonists have narrower evidence. Your doctor may still prescribe them off-label if the clinical reasoning supports it, but you should understand that the evidence base differs.
If you have polycystic kidney disease (PKD), a genetic condition causing multiple cysts in the kidneys, the medication landscape is different. Discuss whether your case warrants SGLT2 inhibitors or other supportive therapies.
If you have sickle cell disease, which can damage kidneys, early testing and treatment are crucial. Ask whether you are a candidate for kidney-protective medications before significant damage occurs.
The cause matters because it shapes both efficacy and risk. A medication that works brilliantly for diabetic kidney disease might offer less benefit in another context.

The Third Question: What Are Your Blood Pressure and Blood Sugar Goals?

These metrics drive medication selection. ACE inhibitors and ARBs remain foundational for blood pressure control and kidney protection. They are inexpensive, well-tolerated, and proven over decades. If you are not already on one, that is the conversation starter.

SGLT2 inhibitors add blood pressure reduction and blood sugar control – a dual benefit that justifies their cost for many patients. GLP-1 agonists do the same, with the added benefit of weight loss and cardiovascular protection.

If your blood pressure is already well-controlled on current medications, adding another agent purely for kidney protection might not make sense. But if you are struggling with blood sugar or blood pressure despite current therapy, a new medication could address multiple problems simultaneously.

The Cost Question: What Help Is Available?

New medications are expensive. But many drug companies offer prescription assistance programmes for those who qualify. Before assuming you cannot afford a medication, ask your doctor’s office about:

Manufacturer copay assistance programmes – most major pharmaceutical companies offer these
Social Security disability benefits – if you qualify
Co-pay assistance programmes – non-profits and foundations often fund these
Patient assistance programmes – for uninsured or underinsured patients
The conversation with your doctor should include cost transparency. If a medication is appropriate but unaffordable, your doctor can advocate with your insurance company, adjust dosing strategies, or identify alternative options.

What to Ask at Your Next Appointment

Come prepared with these specific questions:

What is my current eGFR and UACR, and what do they mean for my kidney health?
What caused my kidney disease, and does that affect which medications I should consider?
Am I currently on an ACE inhibitor or ARB, and if not, why not?
Based on my kidney function, blood sugar control, and blood pressure, am I eligible for SGLT2 inhibitors, finerenone, or GLP-1 agonists?
If I am eligible, which medication would you recommend first, and why?
What are the side effects, and how will we monitor whether the medication is working?
If cost is a barrier, what assistance programmes are available?
How often should I repeat kidney function tests to assess whether the medication is slowing disease progression?

Final Thoughts

The medications available today represent genuine progress. SGLT2 inhibitors reduce kidney failure risk by 30 to 40 percent. GLP-1 agonists lower major kidney event risk by 24 percent. Finerenone prevents scarring and fibrosis. These are not marginal improvements – they are disease-altering interventions.

But they only work if you are on them, and you can only be on them if you and your doctor have the right conversation. That conversation starts with knowing your numbers, understanding your diagnosis, and asking the right questions about eligibility, mechanism, and access.